Xencor, Inc. (NASDAQ:XNCR) Stake Increased by Jane Street Group LLC

Jane Street Group LLC increased its stake in Xencor, Inc. (NASDAQ:XNCR - Free Report) by 18.6% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 168,431 shares of the biopharmaceutical company's stock after buying an additional 26,473 shares during the period. Jane Street Group LLC owned about 0.24% of Xencor worth $3,387,000 at the end of the most recent reporting period.

Several other institutional investors have also recently added to or reduced their stakes in XNCR. Point72 Asset Management L.P. raised its stake in Xencor by 147.3% during the third quarter. Point72 Asset Management L.P. now owns 3,120,229 shares of the biopharmaceutical company's stock valued at $62,748,000 after buying an additional 1,858,440 shares in the last quarter. Logos Global Management LP raised its position in shares of Xencor by 130.8% during the 2nd quarter. Logos Global Management LP now owns 1,500,000 shares of the biopharmaceutical company's stock valued at $28,395,000 after acquiring an additional 850,000 shares in the last quarter. RA Capital Management L.P. bought a new position in Xencor during the third quarter worth $11,563,000. RTW Investments LP acquired a new position in Xencor in the third quarter worth $11,563,000. Finally, Braidwell LP bought a new stake in Xencor during the third quarter valued at $9,380,000.

Insider Activity

In other news, Director Alan Bruce Montgomery sold 13,301 shares of the business's stock in a transaction on Monday, December 2nd. The stock was sold at an average price of $27.03, for a total transaction of $359,526.03. Following the sale, the director now directly owns 9,140 shares of the company's stock, valued at $247,054.20. The trade was a 59.27 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, VP John R. Desjarlais sold 68,684 shares of the business's stock in a transaction dated Monday, November 11th. The stock was sold at an average price of $23.48, for a total value of $1,612,700.32. Following the sale, the vice president now owns 200,104 shares in the company, valued at approximately $4,698,441.92. The trade was a 25.55 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 136,050 shares of company stock worth $3,277,609 over the last three months. Corporate insiders own 5.23% of the company's stock.

Xencor Stock Performance

Shares of NASDAQ:XNCR traded up $0.12 on Friday, hitting $24.13. The company's stock had a trading volume of 4,248,554 shares, compared to its average volume of 626,483. The company has a market capitalization of $1.69 billion, a price-to-earnings ratio of -7.54 and a beta of 0.69. The company has a debt-to-equity ratio of 0.01, a quick ratio of 6.23 and a current ratio of 6.23. Xencor, Inc. has a 12 month low of $15.31 and a 12 month high of $27.24. The stock's 50-day moving average is $23.40 and its two-hundred day moving average is $20.70.

Xencor (NASDAQ:XNCR - Get Free Report) last announced its earnings results on Wednesday, November 6th. The biopharmaceutical company reported ($0.71) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.98) by $0.27. The firm had revenue of $10.70 million during the quarter, compared to analyst estimates of $14.59 million. Xencor had a negative net margin of 232.77% and a negative return on equity of 30.92%. Xencor's revenue was down 81.9% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.40) EPS. On average, equities research analysts forecast that Xencor, Inc. will post -3.71 EPS for the current year.

Analyst Ratings Changes

XNCR has been the topic of a number of recent research reports. Piper Sandler upgraded shares of Xencor from a "neutral" rating to an "overweight" rating and raised their price target for the stock from $20.00 to $30.00 in a research report on Monday, December 2nd. Wedbush reissued an "outperform" rating and issued a $38.00 target price on shares of Xencor in a report on Thursday, November 7th. Royal Bank of Canada lifted their target price on Xencor from $31.00 to $34.00 and gave the company an "outperform" rating in a research note on Thursday, September 26th. BMO Capital Markets reissued an "outperform" rating and issued a $34.00 price target (up previously from $32.00) on shares of Xencor in a report on Friday, November 8th. Finally, Wells Fargo & Company initiated coverage on Xencor in a research report on Thursday, December 12th. They set an "overweight" rating and a $37.00 price objective for the company. One analyst has rated the stock with a hold rating, eight have given a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat, the stock currently has a consensus rating of "Buy" and an average target price of $36.56.

Xencor Profile

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.